Economic and clinical burden associated with respiratory viral infections after allogeneic hematopoietic cell transplant in the United States

Michael G. Ison*, Francisco M. Marty, Nelson Chao, Seung Hyun Moon, Zhiji Zhang, Aastha Chandak

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Allogeneic hematopoietic cell transplant (allo-HCT) recipients are at increased risk for respiratory viral infections (RVIs), which invoke substantial morbidity and mortality. Limited effective antiviral options and drug resistance often hamper successful RVI treatment, creating additional burden for patients and the health care system. Methods: Using an open-source health care claims database, we examined differences in clinical outcomes, health resource utilization, and total reimbursements during the 1-year period following allo-HCT in patients with and without any RVI infection (respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus). RVIs were diagnosed at any time ≤1 year after allo-HCT and identified by International Classification of Disease codes. Analyses were stratified by the presence or absence of acute or chronic graft-versus-host disease (GVHD). Results: The study included 13 363 allo-HCT patients, 1368 (10.2%) of whom had a diagnostic code for any RVI. A higher proportion of patients with any RVI had pneumonia ≤1 year after allo-HCT compared to patients without any RVI, with or without GVHD. Patients with any RVI had higher all-cause mortality risk, longer length of post-allo-HCT hospital stay, higher readmission rate, and higher number of hospital days after allo-HCT compared to patients without the infection (all p <.05). Total unadjusted median reimbursements were higher for those with any RVI and each specific RVI assessed than those without the specific infection, with or without GVHD. Conclusion: Allo-HCT patients with RVIs had significantly worse clinical outcomes and increased health resource utilization and reimbursements during the year following allo-HCT, with or without GVHD.

Original languageEnglish (US)
JournalTransplant Infectious Disease
DOIs
StateAccepted/In press - 2022

Keywords

  • allogeneic HCT
  • clinical burden
  • health care burden
  • respiratory viral infection

ASJC Scopus subject areas

  • Infectious Diseases
  • Transplantation

Fingerprint

Dive into the research topics of 'Economic and clinical burden associated with respiratory viral infections after allogeneic hematopoietic cell transplant in the United States'. Together they form a unique fingerprint.

Cite this